Hepion Pharmaceuticals, Inc. (HEPA)
OTCMKTS
· Delayed Price · Currency is USD
0.1350
-0.1830 (-57.55%)
At close: May 13, 2025
Hepion Pharmaceuticals Employees
Hepion Pharmaceuticals had 22 employees as of December 31, 2023. The number of employees decreased by 3 or -12.00% compared to the previous year.
Employees
22
Change (1Y)
-3
Growth (1Y)
-12.00%
Revenue / Employee
n/a
Profits / Employee
-$599,655
Market Cap
1.48M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
CytoDyn | 9 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Hepion Pharmaceuticals News
- 1 day ago - Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - GlobeNewsWire
- 6 days ago - Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC - GlobeNewsWire
- 2 months ago - Hepion Pharmaceuticals Announces Reverse Stock Split - GlobeNewsWire
- 5 months ago - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - GlobeNewsWire
- 5 months ago - Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group - GlobeNewsWire
- 5 months ago - Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - GlobeNewsWire
- 8 months ago - Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - GlobeNewsWire
- 10 months ago - Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer - Benzinga